End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
48,400 KRW | -1.93% | +10.00% | +33.33% |
2023 | Cosmecca Korea Co., Ltd.(KOSDAQ:A241710) added to S&P Global BMI Index | CI |
2023 | Cosmecca Korea Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 48% by 2026.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Personal Products
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+33.33% | 379M | - | ||
-0.73% | 260B | B- | ||
+18.78% | 20.41B | B+ | ||
0.00% | 19.12B | - | - | |
+18.02% | 12.78B | A- | ||
-15.06% | 9.11B | A- | ||
+27.24% | 8.31B | B+ | ||
+9.08% | 5.91B | B | ||
-8.58% | 4.15B | B+ | ||
-17.45% | 3.81B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- A241710 Stock
- Ratings Cosmecca Korea Co., Ltd.